Amylyx Pharmaceuticals Raises $175M, Shaping Pipeline Ambitions

Amylyx Pharmaceuticals completed a $175 million capital raise by issuing 17.5 million shares at $10 per share. This influx of fresh capital could support the company's pipeline and research initiatives, but shareholders must consider the risk of heightened dilution and ongoing courtroom challenges related to AMX0035's disclosures. The investment narrative hinges on translating the company's innovative drug pipeline into clinical and commercial success.

Amylyx Pharmaceuticals (NYSE:AMLX) recently completed a $175 million capital raise by issuing 17.5 million shares at $10 per share. This significant infusion of fresh capital will support the company's pipeline and research initiatives, particularly in rare diseases such as post-bariatric hypoglycemia, Wolfram syndrome, and ALS. The funding round was announced during the company's presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases^[1].

The capital raise extends Amylyx's financial runway through 2027, providing a solid foundation for its ongoing clinical trials and future product launches. The company's focus on rare diseases aligns with its mission to develop innovative therapies that address unmet medical needs.

Amylyx's pipeline includes avexitide, a first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia. The company is currently executing a Phase 3 trial, LUCIDITY, which aims to enroll 75 participants across 21 US sites by the end of 2025 and expects data in the first half of 2026 Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases^[1]. Additionally, Amylyx is collaborating with Gubra to develop a long-acting formulation of avexitide.

In Wolfram syndrome, Amylyx completed a 48-week study in 12 patients, showing positive trends in markers like C-peptide and HbA1c levels. The company is in ongoing discussions with the FDA to design an efficient study for this rare disease, which affects 3,000 to 3,500 individuals in the US Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases^[1].

For ALS, Amylyx is focusing on axonal degeneration by targeting Calpain 2 with an antisense oligonucleotide called AMX0114. Initial data from the first patient cohort is anticipated by the end of 2025, with dose ranging and biomarker analysis ongoing Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases^[1].

While the capital raise provides a financial boost, shareholders must consider the potential risks associated with heightened dilution and ongoing courtroom challenges related to AMX0035's disclosures. Amylyx's ability to translate its innovative drug pipeline into clinical and commercial success will be critical for the company's future.

Reference List:
Amylyx Pharmaceuticals at H.C. Wainwright: Strategic Advances in Rare Diseases^[1] https://www.investing.com/news/transcripts/amylyx-pharmaceuticals-at-hc-wainwright-strategic-advances-in-rare-diseases-93CH-4233929